Target-volume-based prescription selection for specified adverse-effect levels in automated stereotactic radiosurgery
- Journal
- Physics and imaging in radiation oncology (Q1)
- Published
- 27 September 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Joel A Pogue, Rex Cardan, Farnaz Rahim Li, Rodney Sullivan, Natalie Viscariello, Luke Moradi, et al.
- PMID
- 42861407
- DOI
- 10.1016/j.phro.2026.101093
Why clinicians should know about it
- Picked for Medical Physics (paper of the day, 13 October 2026): Automated SRS model predicts prescription dose from target volume
Abstract
Automated stereotactic radiosurgery (SRS) planning produced consistent dose falloff, enabling adverse-effect-relevant isodose volumes ( IDV ) to be estimated before plan generation. We derived a direct isoeffect prescription dose ( D RX ) model from previously validated target-volume ( V target ) power laws for single-isocenter automated SRS. IDV coefficients and exponents were modelled as continuous functions of relative isodose level ( RIL ), allowing D RX to be solved from V target , desired IDV , and HyTEC brain adverse-effect dose thresholds. Across held-out levels, target-level IDV residuals had a median of 0.2%, an interquartile range of [-5.2%, +7.0%], and a 95% interval of [-12.8%, +27.0%].
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.